ArticleVaccines2022
Lineage 1 Porcine Reproductive and Respiratory Syndrome Virus Attenuated Live Vaccine Provides Broad Cross-Protection against Homologous and Heterologous NADC30-Like Virus Challenge in Piglets.
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Article
- Nanobody-based bioPROTAC for viral protein degradation provides an antiviral strategy for porcine arterivirus.Journal of nanobiotechnology · 2026Article
- A Novel Attenuated NADC30-Like PRRSV Vaccine Candidate Provides Cross-Protection Against Homologous and Heterologous Viral Challenge.Transboundary and emerging diseases · 2026Article
- Article
- Genomic characteristics and epidemic trends of NADC30-like PRRSV in China.Porcine health management · 2025Article
- Porcine Reproductive and Respiratory Syndrome Virus: Challenges and Advances in Vaccine Development.Vaccines · 2025Review
- Whole-Genomic Characterization of Two Different PRRSV-1 Strains Isolated From a Single Pig.Transboundary and emerging diseases · 2025Article
- Porcine reproductive and respiratory syndrome developments: An in-depth review of recent findings.Open veterinary journal · 2024Review
- Evaluation of cross-protection of a reduced-dose PRRS MLV vaccine against the NADC30-like PRRSV challenge.Frontiers in veterinary science · 2024Article
- Evaluation of the cross-protective effect of VR2332 modified live virus vaccine against a recombinant NADC34-like porcine reproductive and respiratory syndrome virus.Frontiers in veterinary science · 2024Article
- Efficacy of a reduced-dosage PRRS MLV vaccine against a NADC34-like strain of porcine reproductive and respiratory syndrome virus.Frontiers in veterinary science · 2024Article
- Article
- Genomic Characterization and Pathogenicity of BJEU06-1-Like PRRSV-1 ZD-1 Isolated in China.Transboundary and emerging diseases · 2023Article
- Article
- Influence of PRRSV-1 vaccination and infection on mononuclear immune cells at the maternal-fetal interface.Frontiers in immunology · 2022Article
- Recent advances in the study of NADC34-like porcine reproductive and respiratory syndrome virus in China.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) is an important pathogen that endangers the swine industry worldwide. Recently, lineage 1 PRRSVs, especially NADC30-like PRRSVs, have become the major endemic strains in many pig-breeding countries. Since 2016, NADC30-like PRRSV has become the predominant strain in China. Unfortunately, current commercial vaccines cannot provide sufficient protection against this strain. Here, an attenuated lineage 1 PRRSV strain, named SD-R, was obtained by passaging an NADC30-like PRRSV strain SD in Marc-145 cells for 125 passages. Four-week-old PRRSV-free piglets were vaccinated intramuscularly with 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.